TMBIM6 antagonist-1 (BIA, 0.5-10 μM, 3 days) significantly and dose-dependently inhibits cell viability in HT1080, MCF7, MDA-MB-2341 and SKBR3 cells, with IC
50
values of 1.7 ± 0.1 μM for HT1080, 2.6 ± 0.4 μM for MCF cells, 2.6 ± 0.5 μM for MDA-MB-231 cells, and 2.4 ± 0.4 μM for SKBR3 cells, respectively.
TMBIM6 antagonist-1 (BIA, 10 μM) treatment decreases cell migration in HT1080, MCF7, MDA-MB-231, and SKBR3 cells, not TMBIM6 KO HT1080 cells.
Cell Viability Assay
Cell Line: | HT1080, MCF7, MDA-MB-2341 and SKBR3 cells. |
Concentration: | 0.5-10 μM. |
Incubation Time: | 3 days. |
Result: | Inhibited cell viability. |
Western Blot Analysis
Cell Line: | WT and TMBIM6 KO HT1080 cells. |
Concentration: | 0, 2, 5 μM. |
Incubation Time: | |
Result: | Downregulated the protein levels of AKT-pS473. |
TMBIM6 antagonist-1 (1 mg/kg, IP 5 days per week during 25 days) significantly impaires cell-driven tumor growth.
Animal Model: |
Six- to eight-week BklNbt:BALB/c/nu/nu old mice (HT1080 and MDA-MB-231 cells).
|
Dosage: | 1 mg/kg. |
Administration: | IP 5 days per week during 25 days. |
Result: | Impaired cell-driven tumor growth. |